Tel: 1-631-626-9181 (USA)   44-207-097-1828 (Europe)

Epigenetic Screening & Profiling Services


Our promise to you:
Guaranteed product quality, expert customer support.


Epigenetic Screening & Profiling Services

Brief Introduction

Creative Biogene is offering epigenetic screening and profiling services. As a well known expert in this field, our talented scientists will provide you first-class services on epigenetic drug discovery. We have built expertise and experience to advance and accelerate your drug discovery programs based on epigenetic targets.

Creative Biogene offers a dedicated epigenetic screening and profiling assay services designed to be flexible and innovative in order to help you success of your projects. High-throughput platform allows us to screen a chemical library against particular epigenetic biochemical targets. Alternatively, our comprehensive collection of epigenetic enzymes, substrates, and off-the-shelf assays enables us analyzing of the activity of a few compounds against several targets.

Epigenetic Screening & Profiling Services Fig.1 The mode of epigenetics mechanisms

Epigenetics, encompassing the wide range of heritable changes in gene expression, which do not result from an alteration in the DNA sequence itself. Epigenetic changes often precede disease pathology, making them valuable diagnostic indicators for disease risk or prognostic indicators for disease progression (Theresa K et al. 2010). Recent studies have shown that epigenetics plays an important role in many types of diseases, including cardiovascular diseases, neurological diseases, metabolic disorders, cancers, as well as several other diseases. Because of the reversible nature of epigenetic events, epigenetics is becoming an increasingly important realm for drug therapies. In fact, in some neurological diseases and cancers, epigenetic drugs are already in use (Sarah et al. 2014).

Epigenetic Screening & Profiling Services Fig.2 Histone deacetylase inhibitors are a possible cancer therapy (Karen 2016)

Creative Biogene offers a great wide of panel for epigenetic enzymes and modifications to help you select a compound to its intended targets. As a pioneer of epigenetic drug discovery services, Creative Biogene has extensive expertise in high-quality screening assays based on a mass of successful projects completed for academic institutions, pharmaceutical and biotechnology companies.

Moreover, to better meet your project demands at each stage of drug discovery, Creative Biogene has enhanced services for screening and profiling now covers more epigenetic targets, all in a convenient manner and at a competitive price. Furthermore, we have flexible assay systems offering single pharmacological dose for hit confirmation or multiple doses for IC50s. We provide a complete report with both raw and analyzed data, graphs, detailed protocols, and a summary of findings. Creative Biogene is confident in offering the best services with the highest level of quality and consistency.

Creative Biogene is dedicated to ensuring all services on epigenetics target screening and profiling are at the highest level of quality. With years of know-how, our experienced scientists will work closely with you to provide help in epigenetics compounds screening and profiling. Creative Biogene is a reliable partner that can help you with greatest chance to succeed.

If you have any special requirements in epigenetics compound screening, please feel free to contact us at or 1-631-626-9181. We are looking forward to working together with your attractive projects.


  1. Theresa K, K., Daniel D De, C., Peter A J. (2010) ‘Epigenetic modifications as therapeutic targets’, NATURE Biotechnology, 28(10), 1069-1078
  2. Karen, W. (2016) ‘Take two: Combining immunotherapy with epigenetic drugs to tackle cancer’, NATURE MEDICINE, 22(1), 8-10
  3. Sarah, H., Karolina, L., Nicole, S., Meghan, L., Sarah, R., Sibaji, S. (2014) ‘Use of Epigenetic Drugs in Disease: An Overview’, Genetics & Epigenetics, 6 9–19

Quick Inquiry

   Please input "biogene" as verification code.